Newamsterdam Pharma (NAMS) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $2.42B
- As of Nov 13, 2026
- P/E
- -11.85x
- Trailing twelve months
- P/B
- 3.83x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- -32.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $2.42B
- As of Nov 13, 2026
- P/E
- -11.85x
- Trailing twelve months
- P/B
- 3.83x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- -32.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-11.85x
Net loss — not comparable
P/B
3.83x
P/S
—
Earnings and dividend metrics▾
Earnings
EPS
-$1.70
Earnings per share
BPS
$5.26
Book value per share
ROE
-32.3%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $1.70 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $5.26 of net assets.
- ROE — shareholder equity shrank by 32.3% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue decreased 34.5% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $29M-34.5%
$29M
Jul–Sep '24
$29M
Jul–Sep '25
$19M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 4, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue decreased 34.5% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 4, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Kastelein Johannes Jacob PieterChief Scientific Officer · Sep 30, 2026Open-market sale50,246 shares · $1.3MAvg. price $25.0369,302 shares held after
- Kastelein Johannes Jacob PieterChief Scientific Officer · Sep 30, 2026Option exercise50,246 shares119,548 shares held after
- Davidson Michael H.Chief Executive Officer · Sep 14, 2026Open-market purchase10,000 shares · $227KAvg. price $22.65792,923 shares held after
- Smither John WDirector · Sep 4, 2026Open-market sale1,600 shares · $41KAvg. price $25.328,760 shares held after
- Gunning Robert WilliamVice President, Controller · Sep 1, 2026Grant or award3,200 shares · $0Avg. price $03,200 shares held after
- Kastelein Johannes Jacob PieterChief Scientific Officer · Aug 24, 2026Open-market sale125,000 shares · $3.4MAvg. price $26.9169,302 shares held after
- Kastelein Johannes Jacob PieterChief Scientific Officer · Aug 24, 2026Option exercise125,000 shares194,302 shares held after
- Kooij Louise FrederikaChief Accounting Officer · Jul 20, 2026Open-market sale105,000 shares · $3.2MAvg. price $30.3396
Show 3 price lots
- 70,200 shares × $29.96$2.1M
- 31,885 shares × $31.05$990K
- 2,915 shares × $31.71$92K
- Kooij Louise FrederikaChief Accounting Officer · Jul 20, 2026Option exercise105,000 shares · $1.2MAvg. price $11.3438
Show 2 price lots
- 80,000 shares × $11.17$894K
- 25,000 shares × $11.9$298K
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Newamsterdam Pharma (NAMS) stock information
NASDAQ
Newamsterdam Pharma (NAMS) is listed on NASDAQ. Its market capitalization is about $2.4B. On trailing-twelve-month earnings the P/E ratio is -11.85, and the P/B ratio is 3.83. Return on equity is -32.3%. These figures are computed in-house from official filings and are reference information only.
Newamsterdam Pharma — frequently asked questions
- What is the P/E ratio of Newamsterdam Pharma (NAMS)?
- On a trailing-twelve-month basis, NAMS trades at a P/E ratio of -11.85. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Newamsterdam Pharma?
- NAMS has a market capitalization of about $2.4B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.